Recent updates in oral terbinafine: Its use in onychomycosis and tinea capitis in the US

Mycoses

Volumn 54, Issue 6, 2011, Pages

  Van Duyn Graham, Lauren ^a   Elewski, Boni E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dermatophytes; Itraconazole; Onychomycosis; Terbinafine; Tinea capitis; Trichophyton

Indexed keywords

ANTIFUNGAL AGENT; GRISEOFULVIN; ITRACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE;

ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; FUSARIUM; HUMAN; LYMPHADENOPATHY; MICROSPORUM; MICROSPORUM CANIS; NAIL INFECTION; ONYCHOMYCOSIS; PRIORITY JOURNAL; REVIEW; SCOPULARIOPSIS; TINEA CAPITIS; TREATMENT DURATION; TRICHOPHYTON; TRICHOPHYTON TONSURANS; TRICHOPHYTON VIOLACEUM; TRICHOPHYTON VIOLACEUM INFECTION; UNITED STATES;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; EUROPE; HUMANS; NAPHTHALENES; ONYCHOMYCOSIS; TINEA CAPITIS; TREATMENT OUTCOME; UNITED STATES;

ARTHRODERMATACEAE; TRICHOPHYTON;

EID: 80053997675     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02038.x     Document Type: Review

References (63)

1. Trovato L, Rapisarda M, Greco A, Galata F, Oliveri S. In vitro susceptibility of nondermatophyte molds isolated from onychomycosis to antifungal drugs. J Chemother 2009; 21: 403-7.
2. Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother 2010; 65: 769-74.
3. Ryder N. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126: 2-7.
4. Chen S, Sorrell T. Antifungal agents. Med J Aust 2007; 187: 404-9.
5. Borgers M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives [with discussion]. Rev Infect Dis 1980; 2: 520.
6. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 2005; 1: 299-306.
7. Abdel-Rahman S, Marcucci K, Boge T, Gotschall R, Kearns G, Leeder J. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999; 27: 770-5.
8. Abdel-Rahman S, Gotschall R, Kauffman R, Leeder J, Kearns G. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65: 465-72.
9. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005; 27: 680-2.
10. Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, Vanmolkot LM. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother 2002; 36: 1712-4.
11. Yasui-Furukori N, Saito M, Inoue Y et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2007; 63: 51-56.
12. Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002; 42: 1211-8.
13. Novartis Pharmaceuticals Corporation. Lamisil (terbinafine hydrochloride) Prescribing Information. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, 2005.
14. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25, 884 patients. Arch Dermatol 1997; 133: 1213-9.
15. Ibrahimi O, Gunawardane N, Sepehr A, Reynolds R. Terbinafine-induced acute generalised exanthematous pustulosis (AGEP) responsive to high dose intravenous corticosteroid. Dermatol Online J 2009; 15: 8.
16. Fletcher CL, Hay RJ, Midgley G, Moore M. Onychomycosis caused by infection with Paecilomyces lilacinus. Br J Dermatol 1998; 139: 1133.
17. Barrett-Bee K, Dixon G. Ergosterol biosynthesis inhibition: a target for antifungal agents. Acta Biochim Pol 1995; 42: 465-79.
18. Ghannoum MA, Welshenbaugh A, Imamura Y, Isham N, Mallefet P, Yamaguchi H. Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes. Mycoses 2010; 53: 311-3.
19. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84.
20. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once daily for 7 and 14days. Clin Exp Dermatol 1994; 19: 121-6.
21. Finlay A. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126(Suppl. 39): 28-32.
22. Kikuchi I, Tanuma H, Morimoto K, Kawana S. Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic-type tinea pedis. Mycoses 2008; 51: 523-31.
23. Rodríguez-Pazos L, Pereiro-Ferreirós MM, Manuel Pereiro J, Toribio J. Onychomycosis observed in children over a 20-year period. Mycoses 2010; Apr 6. doi:
24. Flores J, Castillo V, Franco F, Huata A. Superficial fungal infections: clinical and epidemiological study in adolescents from marginal districts of Lima and Callao, Peru. J Infect Dev Ctries 2009; 3: 313-7.
25. Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl) 2002; 115: 860-5.
26. Ghannoum M, Hajjeh R, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8.
27. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341.
28. Perea S, Ramos MJ, Garau M, Gonzalez A, Noriega AR, del Palacio A. Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. J Clin Microbiol 2000; 38: 3226-30.
29. Fletcher CL, Hay RJ, Smeeton NC. Onychomycosis: the development of a clinical diagnostic aid for toenail disease. Part I. Establishing discriminating historical and clinical features. Br J Dermatol 2004; 150: 701-5.
30. Elewski B. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-29.
31. Ellis D, Watson A, Marley J, Williams T. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-3.
32. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46.
33. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003; 148: 402.
34. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000; 22: 33-52.
35. Crawford F, Young P, Godfrey C et al. Oral treatments for toenail onychomycosis: a systemic review. Arch Dermatol 2002; 138: 811-6.
36. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150: 537-44.
37. Trivedi N, Shah P. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J Dermatol 2010; 55: 198-9.
38. Minati M, Panda P, Satyabrata T, Sujata S, Kaushil M. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2005; 71: 262-6.
39. Gupta AK, Tu LQ. Therapies for onychomycosis: a review. Dermatol Clin 2006; 24: 375.
40. Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol 2010; 35: 658.
41. Segal R, Kritzman A, Cividalli L, Samra Z, David M, Tiqva P. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958-61.
42. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130: 16-21.
43. Gupta AK, Gregurek-Novak T, Konnikov N, Lynde CW, Hofstader S, Summerbell RC. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. JCMS 2001; 5: 206.
44. Ryder N. Activity of terbinafine against serious fungal pathogens. Mycoses 1999; 42: 115-9.
45. Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology 2004; 209: 104.
46. Francesconi G, Valle A, Passos S, Reis R, Galhardo M. Terbinafine (250mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol 2009; 23: 1273-6.
47. Özcan D, Seçkin D, Demirbilek M. In vitro antifungal susceptibility of dermatophyte strains causing tinea pedis and onychomycosis in patients with non-insulin-dependent diabetes mellitus: a case-control study. J Eur Acad Dermatol Venereol 2010; 24: 1442-6.
48. Piraccini B, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010; 62: 411-4.
49. Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-5.
50. Tosti A, Piraccini B, Stinchi C, Venturo N, Bardazzi F, Colombo M. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
51. Tosti A, Piraccini B, Stinchi C, Colombo M. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197: 162-6.
52. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23: 259-62.
53. Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 256.
54. Baran R, Sigurgeirsson B, de Berker D et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157: 149.
55. Gupta A. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005; 4: 481-5.
56. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 2005; 16: 327-30.
57. Jaiswal A, Sharma R, Garg A. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 2007; 73: 393-6.
58. Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500mg day for a week). Mycoses 2009; 52: 72-76.
59. Nakano N, Hiruma M, Shiraki Y, Chen X, Porgpermdee S, Ikeda S. Combination of pulse therapy with terbinafine tablets and topical terbinafine cream for the treatment of dermatophyte onychomycosis: a pilot study. J Dermatol 2006; 33: 753-8.
60. Meadows-Oliver M. Tinea capitis: diagnostic criteria and treatment options. Dermatology Nursing 2009; 21: 281-6.
61. Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Paediatrics 2004; 114: 1312-5.
62. Elewski BE, Caceres HW, DeLeon L et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol 2008; 59: 41.
63. Gupta AK, Adamiak A, Cooper EA. The efficacy and safety of terbinafine in children. J Eur Acad Dermatol Venereol 2003; 17: 627-40.